Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

作者
Philip J. Mease,Taylor S. Blachley,Blessing Dube,Robert R. McLean,Nina Kim,Peter Hur,Alexis Ogdie
出处
期刊:The Journal of Rheumatology [The Journal of Rheumatology Publishing Company Limited]
卷期号:49 (7): 700-706 被引量:5
标识
DOI:10.3899/jrheum.211033
摘要

OBJECTIVE: To evaluate clinical and patient-reported outcomes (PROs) at 6 months after secukinumab initiation in US patients with psoriatic arthritis (PsA). METHODS: Patients with PsA in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry who initiated secukinumab between April 1, 2017, and December 2, 2019, and maintained secukinumab at their 6-month follow-up visit were included. Achievement of minimal disease activity (MDA) among patients not in MDA at initiation; resolution (ie, no evidence) of tender and swollen joint counts, enthesitis, and dactylitis among patients with ≥ 1 of these at initiation; and change in disease activity and PROs were evaluated at 6 months in all patients and in patients who received secukinumab as a first-line biologic. RESULTS: Of the 100 eligible patients included, most (83.0%) were biologic experienced and 17.0% initiated secukinumab as a first-line biologic. At initiation, 75/90 patients (83.3%) with available data were not in MDA; 26/71 (36.6%) with follow-up data achieved MDA at 6 months. Further, 28/68 patients (41.2%) with ≥ 1 tender joint, 24/54 (44.4%) with ≥ 1 swollen joint, 17/28 (60.7%) with enthesitis, and 9/12 (75.0%) with dactylitis at initiation achieved resolution at 6 months. Improvements in clinical manifestations, PRO measures, and work productivity and activity were observed after 6 months among patients with PsA who initiated and maintained secukinumab. CONCLUSION: In this real-world population, patients with PsA who received and maintained secukinumab for 6 months achieved MDA in proportions consistent with clinical trials and demonstrated improvements in clinical manifestations and PROs.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Young发布了新的文献求助10
1秒前
冂xx易云完成签到,获得积分10
1秒前
亦天凛发布了新的文献求助10
2秒前
不敢说话发布了新的文献求助10
2秒前
丘比特的应助被秋是第二个春采纳,获得10
3秒前
吕小菜发布了新的文献求助20
3秒前
4秒前
苏梓淇完成签到,获得积分20
4秒前
5秒前
5秒前
YAM发布了新的文献求助10
5秒前
大个的应助被April采纳,获得10
5秒前
6秒前
6秒前
子云完成签到,获得积分10
7秒前
8秒前
王一硕发布了新的文献求助10
8秒前
今后的应助被亦天凛采纳,获得10
8秒前
cdercder的应助被胡萝卜卜采纳,获得10
8秒前
花薇Liv完成签到,获得积分10
10秒前
积极的中蓝完成签到,获得积分10
10秒前
独特乘云发布了新的文献求助10
12秒前
12秒前
Young完成签到,获得积分20
12秒前
13秒前
激昂的海豚完成签到,获得积分10
13秒前
14秒前
152455完成签到 ,获得积分10
14秒前
14秒前
April发布了新的文献求助10
17秒前
22发布了新的文献求助10
17秒前
17秒前
丘比特的应助被栗子味汽水采纳,获得10
18秒前
xmhxpz完成签到,获得积分10
18秒前
聪慧含芙发布了新的文献求助10
19秒前
wang1完成签到,获得积分10
19秒前
2580852qwe完成签到 ,获得积分10
21秒前
经济管理学渣完成签到,获得积分10
22秒前
lucky发布了新的文献求助10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193438
求助须知:如何正确求助?哪些是违规求助? 9579666
关于积分的说明 21866723
捐赠科研通 7793099
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560719
邀请新用户注册赠送积分活动 2484156